Jeddah, Saudi Arabia—Saudi pharmaceutical company Alpha Pharma has signed an MoU with Biotest AG for Alpha Pharma’s private label of the plasma derivatives products for the kingdom, becoming the first Saudi manufacturer to enter the field of plasma products in the GCC region.
Until the new production infrastructure is operative, Biotest AG will continue to guarantee the supply of plasma-derived products to Saudi Arabia through the supply and distribution agreement with Cigalah Healthcare.
Biotest AG will provide the knowledge and technical expertise and will also supply plasma medicines to Saudi Arabia until Alpha Pharma becomes capable of producing them.
Biotest AG and Alpha Pharma are establishing a new way of partnership with a stepwise approach that includes localization steps in the country, self-sufficiency for plasma proteins products in the Saudi market, and increasing access to therapies for Saudi Arabia patients, Alpha Pharma said in a statement.
“I am proud to see Alpha Pharma establishing strategic partnership with Biotest AG and creating the unique opportunity of being the first Saudi producer of plasma- based innovative therapies for patients in Saudi and other countries across the GCC region,” said Shaikh Yaser Al Naghi, Chairman of Alpha Pharma and Group CEO of Cigalah Healthcare.
Dr Enrico D’Aiuto, Senior Vice President Commercials Operation of Biotest, said, “We are very excited to form part of this strategic collaboration which will contribute to the development of the Saudi Arabian health system and will allow more people to have access to our treatments.”
